Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by pool1212on Feb 23, 2012 8:24am
255 Views
Post# 19571779

article in Retina today Jan/Feb edition

article in Retina today Jan/Feb edition

please find an article on ICO Therapeutics from the January / February edition of Retina Today by Stephen Daily. (Hopefully we will see some more traction around iCo-007 in the coming weeks/months)

https://bmctoday.net/retinatoday/2012/02/article.asp?f=ico-therapeutics

Also, there is a seminar and poster event, in light of celebrate research week at UBC, where Dr Wasan (NGDI and the Faculty of Pharmaceutical Sciences), Andrew Rae (President of ICO), Sonia Zeische (patent agent of Gowling Lafleur Henderson) and Carol Leacy (Program Director of Entrepreneurship UBC) will speak. Speakers will walk students and audience through the process of moving biotechnology advances in global health, specifically neglected diseases from bench science to clinical trials.

https://ngdi.ubc.ca/spotlight/

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities